Medgenics Inc is focused on using genomic medicine to improve the lives of children and adults with rare and difficult-to-treat diseases. The company's flagship product is TARGT (Transduced Autologous Restorative Gene Therapy). The technology allows patients to produce, within their bodies and on a long-term basis, their own natural human protein therapy for the treatment of a range of chronic diseases. The process involves removal, treatment, and re-implantation of micro-organs.